Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Marmoset Research - Scope and Challenges
Published on: June 9, 2023
Population Pharmacokinetic Modeling of Remifentanil in Infants with Unrepaired Tetralogy of Fallot
Jing Chang1,2, Yang Shen1,2, Yue Huang1,2
1Department of Anesthesiology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Rd, Shanghai, 200127, China.
Insights
Tetralogy of Fallot (TOF) does not alter remifentanil pharmacokinetics in infants. This suggests similar anesthetic dosing for infants with TOF and those with normal cardiac anatomy.
Area of Science:
- Anesthesiology
- Pediatric Cardiology
- Pharmacokinetics
Background:
- Congenital heart disease can alter anesthetic pharmacokinetics in children.
- Limited data exists on remifentanil pharmacokinetics in infants with unrepaired Tetralogy of Fallot (TOF).
Purpose of the Study:
- Characterize remifentanil population pharmacokinetics in infants.
- Evaluate the impact of unrepaired TOF on remifentanil pharmacokinetics.
Main Methods:
- Twenty-seven infants (114-360 days) were studied: 16 with TOF, 11 with normal cardiac anatomy.
- Remifentanil (1 μg/kg/min IV) was administered for anesthesia induction and maintenance.
- Population pharmacokinetics were analyzed using NONMEM, with estimates standardized to a 70-kg adult.
Main Results:
- A two-compartment model adequately described remifentanil pharmacokinetics.
- TOF status did not significantly impact the pharmacokinetic model (P > 0.05).
- Population parameter estimates for clearance and volume of distribution were derived, normalized by body weight.
Conclusions:
- Unrepaired TOF does not alter remifentanil pharmacokinetics in infants.
- Similar remifentanil dosing is suggested for infants with and without TOF.
Background:
Although there is literature suggesting that pathophysiologic changes in children with congenital heart disease alter the pharmacokinetics of anesthetics and may result in dosage adjustment, limited information exists regarding the pharmacokinetics of remifentanil in infants with unrepaired tetralogy of Fallot (TOF). The objectives of the current analysis were to characterize the population pharmacokinetics of remifentanil in infants, and to evaluate the effects of TOF on remifentanil's pharmacokinetics.
Methods:
Twenty-seven infants (16 with TOF and 11 with normal cardiac anatomy; aged 114-360 days) scheduled to undergo elective surgery under general anesthesia were recruited in the study. All children received remifentanil 1 μg/kg/min intravenously for anesthesia induction and early maintenance [until ~ 20 min before cardiopulmonary bypass (CPB) for patients with TOF]. Serial arterial blood samples were drawn and analyzed. Population pharmacokinetics of remifentanil was characterized using NONMEM software. The estimates were standardized to a 70-kg adult using a per-kilogram model.
Results:
A two-compartment disposition model adequately described the pharmacokinetics of remifentanil. Besides body weight, the introduction of any other covariates, including TOF status, did not improve the model significantly (P > 0.05). The population parameter estimates for systemic clearance (Cl1) and inter-compartment clearances (Cl2) were 6.03 × (WT/70 kg) and 1.23 × (WT/70 kg) L/min, respectively, and central volume of distribution (V1) and peripheral volumes of distribution (V2) were 19.6 × (WT/70 kg) and 21.7 × (WT/70 kg) L, respectively.
Conclusions:
Unrepaired TOF does not change the pharmacokinetics of remifentanil, suggesting a similar dosage for infants with TOF compared to normal cardiac anatomy infants.
Clinical Trial Registration:
The patient enrollment in this study started at 2012, so we do not have clinic trial number, but we still think this is a valuable research and hope it could be considered for publication.
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Model Approaches for Pharmacokinetic Data: Physiological Models
Conservation of Small Populations
What is Population Genetics?

